Lung cancer (LC), the leading cause of cancer-related deaths worldwide, is a complex and
highly heterogeneous disease. Additional to its biological complexity, LC patients are often …

Recent changes in lung cancer care, including new approvals in first line and the
introduction of high-throughput molecular technologies in routine testing led us to question …

There is a dearth of knowledge about the pathogenesis of premalignant lung lesions,
especially for atypical adenomatous hyperplasia (AAH), the only known precursor for the …

Introduction The incidence rate of lung adenocarcinoma (LUAD), the predominant
histological subtype of lung cancer, is elevated in Asians, particularly in female nonsmokers …

Next-generation sequencing (NGS) technology has demonstrated that the cancer genomes
are peppered with mutations. Although most somatic tumour mutations are unlikely to have …

Recently, non–smoking‐related lung cancer was classified as an independent disease
entity because it is different from tobacco‐associated lung cancer. Non–smoking‐related …

Multiple primary lung cancers (MPLCs) pose diagnostic and therapeutic challenges in clinic.
Here, we orchestrated the cellular and spatial architecture of MPLCs by combining single …

The pleural space, a sterile secluded environment in the thoracic cavity, represents an
attractive metastatic site for various cancers of lung, breast and gastrointestinal origins …

The aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor that is highly
expressed in multiple organs and tissues. Whereas AhR mediates the metabolism of …

Abstract Knowledge of the lung cancer genome has experienced rapid growth over the past
decade. Genome-wide association studies and sequencing studies have identified dozens …